USFDA completes inspection of Nagpur facility, no observation issued: Lupin
New Delhi: Drug firm Lupin said the US health regulator has completed an inspection of its Nagpur facility in Maharashtra without any observation. The product-specific pre-approval inspection by USFDA concluded without any observation, Lupin said in a BSE filing.
Read Also:Lupin gets EIR from USFDA for Nagpur facility
EIREstablishment Inspection ReportLupinUnited States Food and Drug AdministrationUS health regulatorUSFDA
Source : PTIMedical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here
Next Story
NO DATA FOUND
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd